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Tumor drug resistance is the leading cause of chemotherapy treatment failure. One of the more
relevant mechanisms is represented by multidrug resistance (MDR) that leads to a reduced cellular
accumulation of drugs due to increased efflux out of cells by the overexpression of several ATP-
dependent efflux pumps or transporters. These proteins belong to the ATP-binding cassette (ABC)
family and the most studied of them is P-glycoprotein (P-gp). Interestingly, P-gp acts as an efflux
pump for various structurally unrelated anticancer agents (1, 2).
The aim of this issue, that includes nine contributes, is to highlight mechanistic aspects of the P-
gp functions, provide information on the development of in vitroMDR tumor models, and describe
potential strategies to overcome MDR.
Sharom (3) highlights the involvement of P-gp in a complex relationship with its lipid envi-
ronment, which modulates the behavior of its substrates and many functions of the protein (e.g.,
ATP hydrolysis, drug binding, drug transport). Recently, some important principles governing P-
gp–lipid and substrate–lipid interactions, andhow these affect drug binding and transport, have been
shown. In some cells, P-gp is associated with cholesterol-rich microdomains, which may modulate
its functions. It is well known that the protein has also been proposed to operate as a drug translocase
or flippase, moving its substrates from the inner to the outer leaflet of the membrane. The ability of
substrates and modulators to interact with P-gp may depend on their ability to flip–flop between
membrane leaflets. Membrane fluidizers and surfactants may reverse drug resistance, likely via an
indirect mechanism.
On the other hand, Fu (4) introduces an interesting issue describing the localization of P-gp
not only on the plasma membrane but also in many intracellular compartments (i.e., endoplasmic
reticulum,Golgi, endosomes, lysosomes). P-gp can rapidly traffic and recycle among the intracellular
compartments and between cellular organelles and plasma membrane, mainly via the indirect
endosomal pathway. A role of cellular factors, such as RabGTPases, in P-gp trafficking and recycling
is also suggested.
McDermott et al. (5) provide a very detailed guide to the decision-making process for the
development and ongoing maintenance of drug-resistant cancer cell lines. Relevant issues, such
as the choice of the parental cell line, the strategy of cell exposure to anticancer drugs that has to
mimic chemotherapy that patients receive in the clinical practice, as well as dose optimization, are
discussed. Interestingly, McDermott et al. explore the heterogeneity of drug-resistant cell lines in
relation to P-gp highlighting the complexity in developing P-gp resistant tumor models.
Until now, the scientific history of MDR-reversing strategies has been characterized by a repeated
series of failures: indeed, the pharmacological inhibitors of the ABC transporters, such as P-gp,
MDR-related proteins (MRPs), breast cancer resistance proteins (BCRP), have not reached the
sufficient specificity and efficacy to be translated into the clinical practice.
Recently, however, the design of ABC transporters inhibitors has been progressivelymore refined,
e.g., the creation of small libraries of compounds starting from versatile scaffolds or the use of dual
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effect drugs or multitarget drugs (i.e., chemotherapeutic drugs
that are chemically conjugated with an ABC transporters
inhibitor) can increase the selectivity and potency of transporter
inhibitors and modulators, as described in the topic of Zinzi
et al. (6). Although very innovative, these approaches do not
solve the crucial challenge in the field of MDR-reversing strat-
egy, i.e., achieving the maximal efficacy and selectivity against
MDR cells. Recent high-throughput screenings of pharmacolog-
ical libraries identified specific compounds, such as compounds
increasing the generation of reactive oxygen species (ROS) and
depleting cells of the anti-oxidant metabolite glutathione (GSH),
which were unexpectedly more effective in ABC transporter-
overexpressing cells than in ABC transporter-negative cells. This
phenomenon is known as collateral sensitivity (7). The oxidative-
mediated collateral sensitivity is, however, a multifaceted event
in resistant tumors. In this topic, Gauthier et al. (8) demon-
strate, for instance, that the GSH depletion induces apoptosis
in chemoresistant cells overexpressing MRP1, but not in resis-
tant cells overexpressing BCRP. This means that although MDR
cells are generally more damaged than chemosensitive cells by
oxidative stress, the degree of this damage is highly dependent
on the spectrum of ABC transporters expressed by each tumor.
Increasing the GSH efflux via ABC transporters is not the only
strategy that can increase ROS in MDR cells. Changing the activ-
ity of redox sensitive factors that control anti-oxidant enzymes,
phase 2 detoxifying enzymes, and stress response proteins, such
as nuclear factor (erythroid-derived 2)-like 2 (Nrf2), apurinic-
apyrimidinic endonuclease 1/redox factor 1 (APE-1/Ref-1), and
forkhead box O (FoxO), can achieve the same goal. Interestingly,
these transcription factors not only control the redox balance
but also regulate the expression of specific ABC transporters as
reported by Polimeni and Gazzano (9). Therein, their targeting
may result in pleiotropic chemosensitizing benefits against MDR
tumors.
A second approach to improve the selectivity of chemosensi-
tizing agents against MDR cells is the use of nanoparticles, for
the active targeting of chemotherapeutic drugs, chemosensitizing
agents or siRNA within the resistant tumor as proposed in this
topic byConde et al. (10). Several open questions need to be solved
before the translation of nanoparticle-based approaches into the
clinical practice, such as the biocompatibility and the long-term
safety of nanoparticles. Once the first phase I–phase II clinical
trials and observational studies have been concluded, these issues
will be clarified and nanoparticles may become useful tools also
for the delivery of collateral sensitivity inducers or agents targeting
redox sensitive factors within MDR cells.
Cancer stem cells (CSCs) exhibit several mechanisms of resis-
tance against anticancer drugs that are mainly represented by the
expression of ABC transporters and activation of different signal-
ing pathways (e.g., Wnt/β-catenin signaling, Hedgehog, Notch,
Akt/PKB). Thus, compounds able to modulate MDR on CSC
membranes could induce cytotoxicity in these cells, as described
by Zinzi et al. (11).
Two models have been suggested to explain the connection
between MDR and CSCs: the “original” MDR model according
to which, after exposure to the chemotherapeutic agent, only
CSCs expressing ABC transporters repopulate the tumor, and the
“acquired” MDR model according to which after chemotherapy,
only CSCs survive and this population of survival cells, after
mutations, originates new and more aggressive drug-resistant cell
phenotypes. Thus, the combination of CSC targeting agents with
novel or conventional cytotoxic drugs could lead to a potenti-
ated effect. An innovative multimodal strategy, i.e., an approach
in which specific CSC targeting drugs exert simultaneously the
ability to circumvent tumor drug resistance (by ABC transporter
modulation) and to exert cytotoxic activity toward CSCs and the
corresponding differentiated tumor cells, may be hypothesized.
Targeting ABC transporters is a challenge not only limited to
tumors cells but it also involves the tumor microenvironment in
specific districts: as demonstrated in this topic by Adkins et al.,
breast cancer cells metastasizing within central nervous system
are rich of P-gp and are surrounded by a complex vasculature
expressing P-gp as well (12). This situation, which is common to
other metastatic cancers, creates “MDR niches,” making harder
the full eradication of resistant cells and easier the tumor relapse.
Finding compounds overcoming P-gp activity in both the tumor
cell and the tumor microenvironment-associated cells is a future
open challenge in the field of MDR-reversing strategies.
This topic has reviewed pharmacological strategies to overcome
MDR. Fighting MDR involves multiple skills and know-how,
including the ability to develop suitable in vitro drug-resistant
tumor models, the understanding of the ABC transporter func-
tions, the use of medicinal chemistry, the production of new
nanomaterials, the analysis of the biochemical features of MDR
cells, and themanagement of clinical trials. Suchmultidisciplinary
approach ismandatory to opennewperspectives against chemore-
sistant tumors.
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